PHAS - PhaseBio announces pivotal data for anti-platelet agent

PhaseBio Pharmaceuticals (PHAS -8.0%) and its co-development partner SFJ Pharmaceuticals shared data from an ongoing pivotal Phase 3 trial for the company’s lead product candidate, bentracimab. The 150-patient study was designed to evaluate bentracimab in the reversal of ticagrelor’s antiplatelet effects in patients who have undergone urgent surgery or are at the risk of life-threatening bleeding. According to the pre-specified interim analysis, bentracimab, a human monoclonal antibody, reached the primary endpoint by leading to a quick and lasting reversal effect on ticagrelor, PhaseBio (NASDAQ:PHAS) said. Over 90% of subjects in the trial achieved the co-primary endpoint of good or excellent hemostasis within 24 hours from the start of the therapy. On the safety front, 5.3% of subjects experienced thrombotic events related to bentracimab. While the drug appeared to be well-tolerated, there were five treatment-related non-serious adverse events among three patients. PhaseBio (PHAS) Chief Medical Officer John Lee reaffirmed that the company’s

For further details see:

PhaseBio announces pivotal data for anti-platelet agent